study to assess efficacy of AZD1236 in patients with cystic fibrosis - CYBER
Study identifier:D4260C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis
Medical condition
cystic fibrosis
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD1236, Placebo
Sex
All
Actual Enrollment
44
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Dec 2009
Primary Completion Date: -
Estimated Study Completion Date: 01 Aug 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 May 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD1236 Oral tablet, 75 mg twice daily during 4 weeks |
| Placebo Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Andrew J Lockton
AstraZeneca R&D Charnwood
